AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
view all Clinical Trials
Overview
Objectives
- Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy.
- Secondary: To test the hypothesis that the relative efficacy of apixaban over aspirin increases with the severity of atrial cardiopathy.
Contact
For more information about this trial or to inquire about eligibility, call 215-707-7845 or email sandra.combs@tuhs.temple.edu.